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A randomized, double-blind, placebo-controlled
study assessing the safety and tolerability
of regadenoson in subjects with asthma
or chronic obstructive pulmonary disease
Bruce M. Prenner, MD,a Stan Bukofzer, MBBCh, MMed (Int),b Sarah Behm, BS,b
Kathleen Feaheny, MS,b and Bruce E. McNutt, MDb
Background. Adenosine receptor stress agents for myocardial perfusion imaging (MPI)
may cause A2B and/or A3 receptor-mediated bronchoconstriction, of particular concern to
physicians testing patients with asthma or chronic obstructive pulmonary disease (COPD).
Methods. A Phase 4, randomized, double-blind study (NCT00862641) assessed the safety of
the selective A2A receptor agonist, regadenoson, compared with placebo in subjects with asthma
or COPD who represented likely candidates for MPI.
Results. Overall, 356 and 176 subjects with asthma and 316 and 151 subjects with COPD
received regadenoson and placebo, respectively. The percentage of subjects experiencing a
>15% decrease in FEV1 from baseline to any assessment up to 24 hours post-baseline was not
statistically significantly different between the regadenoson and the placebo groups in the
asthma or COPD stratum. Dyspnea, the most frequent respiratory adverse event, occurred with
higher incidence (P < .0001) in the regadenoson group than the placebo group in the asthma
(10.7% vs 1.1%) and COPD (18.0% vs 2.6%) strata. No subjects experienced severe bron-
choconstriction, although the occurrence of such reactions with adenosine receptor agonists
cannot be ruled out, such that caution is advised.
Conclusions. This information may be helpful to physicians selecting a pharmacologic
stress agent for MPI in patients with asthma or COPD. (J Nucl Cardiol 2012;19:681–92.)
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INTRODUCTION
Myocardial perfusion imaging (MPI) is a widely
used technique to aid the diagnosis and the evaluation of
coronary artery disease. Pharmacologic stress agents are
indicated for use in patients who are unable to undergo
adequate exercise stress due to physical limitations or
medical constraints.1 Adenosine, dipyridamole, and
regadenoson increase myocardial blood flow by causing
coronary vasodilation via stimulation of adenosine A2A
receptors.2 Pharmacologic stress agents that are non-
selective adenosine receptor agonists activate all aden-
osine receptor subtypes (A1, A2A, A2B, and A3) to
different extents at recommended clinical doses.1 The
activation of the A1, A2B, and A3 receptors can elicit a
variety of undesirable responses including atrioventric-
ular block (A1 receptor), peripheral vasodilation (A2B
receptor), and bronchoconstriction (A2B and A3 recep-
tors).1 The risk of bronchoconstriction is of particular
concern for physicians considering pharmacologic stress
MPI in patients with asthma or chronic obstructive
pulmonary disease (COPD).
As regadenoson has a greater affinity for the A2A
receptor and much lower affinity for the other adenosine
receptor subtypes at recommended clinical doses1 com-
pared with adenosine or dipyridamole, the risk of
bronchoconstriction in patients with reactive airways
could be lower.3,4 Two pilot studies have been con-
ducted in subjects with asthma5 and COPD.6 In the first
pilot study, Leaker et al5 conducted a randomized,
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double-blind, placebo-controlled, crossover study of 48
subjects with mild or moderate asthma who demonstrated
bronchial reactivity to adenosine monophosphate. The
mean ratio of the forced expiratory volume in 1 second
(FEV1) to the baseline FEV1 was higher in the regade-
noson group than the placebo group from 10 to
60 minutes after drug administration.5 Mean FEV1 in
the regadenoson group was not statistically different from
the placebo group at any of the scheduled assessments up
to 120 minutes post-dose. Bronchoconstrictive reactions
(defined by Leaker et al as a [15% reduction in FEV1
from baseline) were experienced by similar percentages
of subjects who received regadenoson (4.3% [2/47]) and
placebo (4.2% [2/48]), and were not associated with
pulmonary adverse events, serious adverse events, or
study termination.5 In the second pilot study, Thomas
et al6 performed a randomized, double-blind, placebo-
controlled crossover trial of regadenoson safety in 49
subjects with moderate or severe COPD. No differences
were observed between subjects who received regadeno-
son and those who received placebo across lung function
parameters, which included FEV1, forced vital capacity
(FVC), respiratory rate, pulmonary examinations, and
oxygen saturation.6 There were no statistically significant
differences in the mean FEV1 between the regadenoson
group and the placebo group at any of the scheduled
assessments up to 120 minutes post-dose. Bronchocon-
strictive reactions (defined by Thomas et al as a [15%
reduction in FEV1 from baseline) occurred in 12.2%
(6/49) of subjects who received regadenoson and 6.1%
(3/49) of subjects who received placebo. These changes
were not associated with pulmonary adverse events (other
than throat tightness in one subject who received regad-
enoson), changes in vital signs, pulmonary examination,
or oxygen saturation, and no treatment was required.6
This study was conducted to further investigate the safety
of regadenoson for use in patients with asthma or COPD.
MATERIALS AND METHODS
A Phase 4, multicenter, randomized, double-blind,
placebo-controlled study to assess the safety and the
tolerability of regadenoson in subjects with asthma and/
or COPD who represent those likely to be referred for
MPI studies was conducted (NCT00862641). The study
was not designed to assess the efficacy of regadenoson
for MPI in subjects with asthma or COPD; thus, subjects
did not undergo imaging studies following administra-
tion of study drug.
Inclusion and Exclusion Criteria
Subjects with asthma and/or COPD were eligible
for enrollment if they were C18 years of age. In order to
represent patients who were likely candidates for MPI
procedures, subjects were to have ongoing coronary
artery disease, or have at least two of the following risk
factors for coronary artery disease: type 2 diabetes,
hypertension, hypercholesterolemia, current or history
of cigarette smoking (minimum 10 pack years expo-
sure), or obesity (body mass index [BMI] [30 kg/m2).
Asthmatic subjects were to have reasonably well-con-
trolled asthma (as demonstrated by an FEV1 C60%
predicted) with the frequency and severity of their
symptoms having remained unchanged within 30 days
prior to study drug administration. COPD was defined
by an FEV1/FVC ratio \0.70.
Subjects were to be excluded if they had partic-
ipated in another drug study or received an
investigational drug within 30 days prior to screening.
Subjects were not included if they had a history of
additional clinically significant illnesses, medical con-
ditions, or laboratory abnormalities within 2 weeks
prior to screening that, in the investigator’s opinion,
would hinder study procedures or confuse the inter-
pretation of data. Furthermore, subjects with a history
of second- or third-degree heart block or sinus node
dysfunction (unless the subject had a functioning
pacemaker), symptomatic hypotension, or who had a
respiratory infection within 2 weeks or surgery within
3 months prior to randomization, were excluded.
Subjects were required to have a stable medica-
tion regime for a minimum of 30 days prior to study
drug administration, without an exacerbation of their
asthma or COPD during this same period. Subjects
must not have started on a course of oral or injectable
corticosteroids, inhaled steroid combination with a
long-acting b2 agonist (oral or inhaled) or anticholin-
ergic, or had undergone a change in dose of such
medications B30 days prior to study drug administra-
tion. Subjects must not have started or changed the
dose of any leukotriene antagonists, mast cell stabi-
lizers (cromones), or 5-lipoxygenase antagonists B7
days prior to study drug administration. Subjects were
not to have an allergy or intolerance to aminophylline
or regadenoson or any of its excipients.
Female subjects who were pregnant or had a
positive pregnancy test within 24 hours prior to ran-
domization, lactating, or of childbearing potential and
refused to use a medically acceptable form of contra-
ception until the follow-up visit was complete were also
excluded.
Written informed consent and privacy language
was obtained from all subjects or legally authorized
representatives prior to any study-related procedures,
in accordance with the respective Instructional Review
Boards or Ethics Committees and appropriate Federal
regulations.
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Concomitant Medications
Subjects had to abstain from any intake of methyl-
xanthine-containing foods and beverages within
12 hours prior to study drug administration until the
follow-up visit. In addition, all subjects had to abstain
from theophylline for 12 hours prior to the Day 1 visit.
When possible, dipyridamole was withheld for at least 2
days prior to study drug administration. Subjects were
not allowed to alter their concomitant medications from
study drug administration until the follow-up visit.
Randomization and Blinding
The study was a double-blind, randomized, parallel
group study stratified by the underlying condition of asthma
or COPD. Subjects who met the inclusion and exclusion
criteria were randomized into the study using a 2:1
(regadenoson/placebo) computer-generated randomization
schedule by stratum (asthma or COPD). The randomization
schedule was generated by Astellas. Study drug assignment
was to be revealed only for reasons relating to the safety of
the subject, when knowledge of the assigned drug was
needed to make critical therapeutic decisions.
Drug Administration
Subjects were to abstain from eating and drinking for
30 minutes prior to and 30 minutes post-study drug
administration, and were to abstain from smoking for 3
hours prior and 8 hours post-study drug administration.
Subjects received either a 0.4 mg/5 mL (0.08 mg/mL)
intravenous bolus injection of regadenoson or matching
placebo, administered over approximately 10 seconds,
followed by a 5-mL 0.9% saline flush. Subjects were
placed in either a reclining or a supine position prior to
dosing and remained in that position for the first 2 hours
(except during spirometry measurements). The protocol
did not require physicians to administer short-acting b2
agonists (bronchodilators) prior to the administration of
regadenoson, although subjects were instructed to con-
tinue their normal prescribed respiratory medications
prior to study drug administration. After study drug
administration, short-acting b2 agonists were used for
mild-to-moderate respiratory or cardiac symptoms, fol-
lowed by intravenous aminophylline if the short-acting b2
agonist did not successfully treat the symptoms. Ami-
nophylline was used as the primary treatment for any
severe and/or persistent respiratory or cardiac symptoms.
Safety Assessments
The majority of adverse events for regadenoson occur
during the 2-hour period after administration; thus, the
primary safety objective selected for this study was to
determine the percentage of subjects with a [15%
decrease in FEV1 from baseline to the 2-hour post-
baseline assessment. A [15% decline in FEV1 from
baseline was chosen as a clinically meaningful indication
of airway obstruction. Used in the diagnosis of asthma, a
[15% decrease in FEV1 in an exercise challenge test is
diagnostic of exercise-induced bronchoconstriction.7,8
Table 1. Asthma and COPD severity criteria9,10
Asthma
Modified version of National Heart, Lung, and Blood Institute criteria9
Step 1: Inhaled short-acting b2 agonist when needed
Step 2: Low-dose inhaled corticosteroid OR cromolyn, leukotriene receptor antagonist, nedocromil, or
theophylline
Step 3: Low-dose inhaled corticosteroid and long-acting b2 agonist OR medium-dose inhaled corticosteroid OR
low-dose inhaled corticosteroid, and either leukotriene receptor antagonist, theophylline, or zileuton
Step 4: Medium-dose inhaled corticosteroid and long-acting b2 agonist, OR medium-dose inhaled corticosteroid
and either leukotriene receptor antagonist, theophylline, or zileuton
Step 5: High-dose inhaled corticosteroid and long-acting b2 agonist
Step 6: High-dose inhaled corticosteroid and long-acting b2 agonist and oral steroids
COPD
GOLD criteria10
Stage I (mild): FEV1/FVC\0.70, FEV1 C80% predicted
Stage II (moderate): FEV1/FVC\0.70, 50%BFEV1\80% predicted
Stage III (severe): FEV1/FVC\0.70, 30%BFEV1\50% predicted
Stage IV (very severe): FEV1/FVC\0.70, FEV1\30% predicted or FEV1\50% predicted plus chronic respiratory
failure
COPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Although, changes in respiratory function may be
expected to occur before 2 hours post-baseline, subjects
with a [15% reduction in FEV1 from baseline to this
assessment would represent those with significant, persis-
tent respiratory function changes. FEV1 measurements
were obtained at 5 minutes, 15 minutes, 1 hour, 2 hours, 8
hours, and 24 hours (follow-up visit) post-study drug
administration. The effect of baseline asthma and COPD
severity on FEV1 decreases was also investigated. Asthma
severity was assessed jointly by the Astellas Medical
Director and an external asthma expert (Dr Bruce M.
Prenner, Allergy Associates Medical Group, Inc.) using a
modified version of the National Heart, Lung, and Blood
Institute (NHLBI) Expert Panel Report 3 stepwise
approach for managing asthma, based on the type and
dose of asthma medication (Table 1).9 In the event of a
difference of opinion between the parties, the classification
of the asthma expert was utilized. COPD severity was
assessed by the investigator at each study site using the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria, based on lung function parameters
(Table 1).10 Oxygen saturation was measured continu-
ously by pulse oximetry from baseline through the 2-hour
post-baseline assessment; measurements at 1, 2, 5, 10, 15,
and 30 minutes, and 1 and 2 hours post-baseline were
analyzed.
Other safety assessments included the incidence of
selected respiratory adverse events (defined prior to
unblinding as dyspnea, wheezing, obstructive airways
disorder, exertional dyspnea, and tachypnea [MedDRA
version 11.1 preferred terms]) up to 24 hours post-
regadenoson administration, and the use of short-acting
bronchodilators in response to these events. Vital signs
(heart rate and blood pressure) and 12-lead electrocar-
diograms (ECGs) were monitored at selected intervals
up to 24 hours post-study drug administration.
Statistical Analyses
The protocol planned for the enrollment of 450
subjects in each of the asthma and COPD strata (with
300 subjects receiving regadenoson in each stratum).
The analysis population consisted of all randomized
subjects who received any amount of study drug.
Descriptive statistics were calculated for continuous
variables, and frequencies and percentages were dis-
played for categorical data. All statistical comparisons
were made using 2-sided tests at the a = 0.05 significance
level unless stated otherwise. All null hypotheses were of
no treatment difference and all alternative hypotheses
were 2-sided. Demographics and other baseline charac-
teristics were summarized using descriptive statistics;
statistical comparisons between the treatment groups
were summarized. One-way analysis of variance
(ANOVA) was used for continuous variables and Fisher’s
exact test or chi-square for the discrete variables.
Protocol Amendments
Notable protocol amendments made after the trial
had commenced included the modification of the
primary endpoint to be pulmonary function as measured
by the proportion of subjects with a [15% decrease in
FEV1 from baseline to the 2-hour post-baseline assess-
ment, rather than the assessment of selected respiratory
adverse events (‘‘protocol amendment 3’’; made after
692 subjects had been enrolled). Also under protocol
amendment 3, an additional inclusion criterion was
added for COPD subjects (FEV1/FVC \70%), and two
additional inclusion criteria were added for asthma
subjects (FEV1 C60% predicted and the frequency and
Figure 1. Subject disposition flow diagrams for the asthma
(A) and COPD (B) disease strata.
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severity of their symptoms having remained unchanged
within 30 days prior to study drug administration). The
addition of current or history of cigarette smoking
(minimum 10 pack years exposure) as a risk factor for
coronary artery disease (‘‘protocol amendment 2’’) was
added after 81 subjects had been enrolled.
RESULTS
Subject Disposition and Baseline
Characteristics
In total, 1,009 subjects were randomized from 48
study centers in the United States. Study drug was
administered to 999 subjects, of which 356 and 176
subjects with asthma and 316 and 151 subjects with
COPD received regadenoson and placebo, respectively
(Figure 1). Five subjects in each disease stratum (four
who were randomized to receive regadenoson and one
who was randomized to receive placebo) were random-
ized but did not receive study drug.
Baseline characteristics were generally similar
between subjects who received regadenoson and
subjects who received placebo in the two disease strata,
although subjects with COPD who received regadeno-
son had a statistically significantly lower mean body
weight and BMI than subjects who received placebo
(Table 2). Baseline asthma or COPD severity9,10 was
similar between subjects who received regadenoson or
placebo, although a statistically significant difference
(P = .0095) was observed for the distribution of asthma
subjects due to the Step 4 asthma category, which
comprised a greater number of subjects who received
regadenoson than placebo. These differences are likely
an artifact of the randomization (which was not stratified
by asthma/COPD severity).
Safety Assessments
The percentage of subjects with a[15% decrease in
FEV1 from baseline to the 2-hour post-baseline assess-
ment was not statistically significantly different between
the regadenoson group and the placebo group in either
the asthma stratum (1.1% [4/351] vs 2.9% [5/174],
respectively) or the COPD stratum (4.2% [13/313] vs
5.4% [8/147], respectively) (Table 3). Furthermore,
Table 2. Baseline subject demographics, including medical history and risk factors for coronary artery
disease
Parameter









Female, n (%) 115 (65.3) 245 (68.8) 67 (44.4) 132 (41.8)
Mean age (years) (SD) 52.3 (11.6) 52.2 (11.8) 60.0 (10.4) 60.4 (10.7)
Age C65 years, n (%) 28 (15.9) 52 (14.6) 56 (37.1) 127 (40.2)
Mean weight (kg) (SD) 99.5 (23.7) 97.2 (21.6) 94.2 (23.8)* 89.5 (20.3)*
Mean BMI (kg/m2) (SD) 35.5 (8.0) 35.2 (7.4) 32.4 (7.3)** 30.9 (6.5)**
Race, n (%)
White 128 (72.7) 283 (79.5) 136 (90.1) 284 (89.9)
Black/African American 45 (25.6) 61 (17.1) 13 (8.6) 22 (7.0)
Other 3 (1.7) 12 (3.4) 2 (1.3) 10 (3.2)
Medical history, n (%)
COPD 4 (2.3) 10 (2.8) 151 (100) 316 (100)
Asthma 176 (100) 356 (100) 8 (5.3) 17 (5.4)
Current CAD 21 (11.9) 34 (9.6) 35 (23.2) 63 (19.9)
Ongoing CAD risk factors
Hypercholesterolemia 120 (68.2) 243 (68.3) 104 (68.9) 215 (68.0)
Hypertension 134 (76.1) 250 (70.2) 115 (76.2) 237 (75.0)
Obesity (BMI[30 kg/m2) 132 (75.0) 282 (79.2) 94 (62.3) 163 (51.6)
Type 2 diabetes 48 (27.3) 98 (27.5) 51 (33.8) 77 (24.4)
Current smoker, or history of smokinga, n (%) 57 (32.4) 122 (34.3) 130 (86.1) 268 (84.8)
BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; SD, standard deviation.
*P = .0276, **P = .0301.
aSmoking defined as C10 pack years.
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there were no significant differences in the percentage of
subjects with a[15% decrease in FEV1 from baseline to
any assessment up to the follow-up visit, 24 hours post-
baseline (Table 3). The percentage of subjects with a
[15% decrease in change in FEV1 was not affected by
baseline disease severity in either the asthma or COPD
stratum (Table 4). The largest individual absolute
decreases in FEV1 in the regadenoson group were
1.1 L (33.1%) and 0.79 L (30.7%) in the asthma and
COPD strata, respectively; the lowest measurements
were both obtained at the 15-minute post-dose assess-
ment (Table 5). The largest individual percentage
decreases in FEV1 in the regadenoson group were
34.4% (0.64 L; 15 minutes post-dose) and 44.6%
(0.78 L; 5 minutes post-dose) in the asthma and COPD
stratum, respectively (Table 5). The largest individual
FEV1 decreases were generally slightly lower in the
placebo group, with the lowest individual measurements
obtained at a variety of post-dose assessments from 5
minutes to 2 hours post-dose (Table 5).
Decreases in FEV1 and FVC from baseline to 2
hours post-dose for the regadenoson group were similar
to, or less than the placebo group (Table 6).
Decreases in oxygen saturation are a severe man-
ifestation of acute pulmonary decomposition. Changes
in oxygen saturation from baseline to any post-baseline
assessment did not demonstrate statistically significant
decreases in the regadenoson group compared with the
placebo group in either the asthma or COPD stratum,
with the exception of the 30-minute post-baseline
measurement in the COPD stratum (-0.8% in the
regadenoson group vs 0% in the placebo group). The
greatest individual decreases in oxygen saturation in the
regadenoson group were -12.4% (97.9% to 85.5%) and
-12.7% (98.2% to 85.5%) in the asthma and COPD
strata, respectively; both lowest measurements were
recorded at the 30-minute post-dose assessment
(Table 5). The subjects with the greatest individual
decreases in oxygen saturation and the aforementioned
subjects with the greatest individual decreases in FEV1








[95% CI]a P valueb
Asthma stratum
Minute 5 1/161 (0.6) 5/322 (1.6) 0.9% [-0.9%, 2.8%] .3941
Minute 15 4/175 (2.3) 2/355 (0.6) -1.8% [-4.1%, 0.6%] .0685
Hour 1 1/86 (1.2) 0/175 (0.0) -1.1% [-3.2%, 1.0%] .2032
Hour 2c 5/174 (2.9) 4/351 (1.1) -1.8% [-4.5%, 1.0%] .1451
Hour 8d 2/23 (8.7) 2/40 (5.0) -3.9% [-17.5%, 9.7%] .4151
Follow-upe 2/83 (2.4) 3/173 (1.7) -0.7% [-4.4%, 3.0%] .7573
At any visitf 12/176 (6.8) 13/356 (3.7) -3.2% [-7.5%, 1.0%] .1004
COPD stratum
Minute 5 4/132 (3.0) 10/272 (3.7) 0.7% [-3.0%, 4.4%] .7315
Minute 15 5/150 (3.3) 9/314 (2.9) -0.4% [-3.9%, 3.1%] .8134
Hour 1 1/13 (7.7) 2/30 (6.7) -8.7% [-25.8%, 8.4%] .1138
Hour 2c 8/147 (5.4) 13/313 (4.2) -1.2% [-5.4%, 3.1%] .5790
Hour 8d 4/14 (28.6) 5/39 (12.8) -20.7% [-48.4%, 7.1%] .0971
Follow-upe 2/27 (7.4) 4/58 (6.9) -2.0% [-15.4%, 11.3%] .7237
At any visitf 13/151 (8.6) 31/316 (9.8) 1.2% [-4.3%, 6.7%] .6675
CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.
aTreatment effect and 95% confidence intervals were calculated using weighted averages where the weights adjusted for the
number of subjects in each investigative site. These weights reflect their relative contribution to the Mantel-Haenszel statistic.
bCochran-Mantel-Haenszel test stratified by investigative site. Sites with\15 subjects were pooled.
cPrimary safety outcome.
dOnly includes subjects with FEV1 Hour 2 results not within 15% of baseline results or who were symptomatic at Hour 2.
eFollow-up: 24 hours post-drug administration; includes subjects with FEV1 Hour 2 results not within 15% of baseline results or
who were symptomatic at Hour 2 and all subjects randomized under protocol amendment 3.
fFEV1 post-baseline assessments were performed at the Minute 5, Minute 15, Hour 1, Hour 2, Hour 8, and follow-up visit.
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were not the same subjects. The greatest individual
decreases in oxygen saturation in the regadenoson group
were less than the corresponding decreases observed in
the placebo group (-15.2%, 5 minutes post-dose and
-14.4%, 3 to 7 hours post-dose for the asthma and
COPD strata, respectively) (Table 5).
Two subjects in the placebo group (one with COPD
and one with asthma) and two subjects in the regade-
noson group (both with COPD) had both a decrease in
FEV1[15% from baseline and a potentially meaningful
decrease in oxygen saturation (to \92% of baseline
level). One of the subjects who received regadenoson
(COPD stratum) had a[15% FEV1 decrease and oxygen
saturation drop at 15 minutes and 2 hours post-baseline
whereas all the other concurrent falls were at 2 hours
post-baseline.
Of the identified selected respiratory adverse events
(defined prior to unblinding as dyspnea, wheezing,
obstructive airways disorder, exertional dyspnea, and
tachypnea), dyspnea occurred most frequently, with a
higher incidence (P \ .0001) in the regadenoson group
than the placebo group in both the asthma (10.7% [38/
356] vs 1.1% [2/176]) and COPD strata (18.0% [57/316]
vs 2.6% [4/151]). In the asthma stratum, wheezing
occurred in 3.1% (11/356) of the regadenoson group and
1.1% (2/176) of the placebo group, and obstructive
airways disorder (reported as airway constriction) was
reported in one regadenoson group subject. In the COPD
stratum, all other selected respiratory adverse events
occurred in \1% of subjects. In subjects with a [15%
decrease in FEV1 from baseline to the 2-hour post-
baseline assessment, no subjects who received placebo
in either disease stratum or any subject in the asthma
stratum reported a selected respiratory adverse event up
to 1 day post-study drug administration. In the COPD
stratum, two subjects with a [15% decrease in FEV1
from baseline to the 2-hour post-baseline assessment
who received regadenoson reported dyspnea within
2 hours of study drug administration and two subjects
reported dyspnea within 1 day of study drug adminis-
tration. One subject in the COPD stratum with a [15%
decrease in FEV1 from baseline to the 2-hour post-
baseline assessment who received regadenoson reported
wheezing within 1 day of study drug administration.
There were no significant differences between the
regadenoson and the placebo groups (for either disease
stratum) in the number of subjects who were using
short-acting b2 agonists at the time of these selected
Table 4. Subjects with a[15% decrease in FEV1 from baseline to the 2-hour post-baseline assessment




n/N (%) P valuea
Asthma stratumb,c
Step 1 0/47 (0) 2/107 (1.9) .3368
Step 2 0/27 (0) 1/33 (3.0) .2207
Step 3 3/31 (9.7) 1/49 (2.0) .1673
Step 4 0/23 (0) 0/84 (0) –
Step 5 1/25 (4.0) 0/44 (0) .1904
Step 6 1/2 (50.0) – –
Unable to classifyd 0/19 (0) 0/34 (0) –
COPD stratume
Stage I 1/20 (5.0) 0/43 (0) –
Stage II 1/72 (1.4) 9/148 (6.1) .1353
Stage III 2/28 (7.1) 2/60 (3.3) .6877
Stage IV 1/2 (50.0) 0/4 (0) .3173
Not calculatedf 3/25 (12.0) 2/58 (3.4) .1749
COPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.
aCochran-Mantel-Haenszel test stratified by investigative site. Sites with\15 subjects were pooled.
bAsthma severity assessed using a modified version of the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel Report
3 (Table 1).9
cThe distribution of baseline asthma severity categories was significantly different between the regadenoson and placebo groups
(P = .0095) because of a greater percentage of Step 4 subjects in the regadenoson group than in the placebo group.
dSubjects were not classified if no prior medications reported.
eCOPD severity assessed using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (Table 1).10
fSubjects enrolled prior to protocol amendment 2 and who did not complete test for classifying severity and/or subjects who did
not meet GOLD criteria for severity.
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respiratory adverse events (Table 7). It should be noted
that although the protocol did not require physicians to
administer short-acting b2 agonists prior to the admin-
istration of regadenoson, subjects may have been
receiving these agents as part of their routine care.
Adverse events were experienced by 235/356
(66.0%) subjects who received regadenoson and 55/
176 (31.3%) subjects who received placebo in the
asthma stratum, and 193/316 (61.1%) subjects who
received regadenoson and 38/151 (25.2%) subjects who
received placebo in the COPD stratum. Adverse events
that occurred with an incidence rate of [10% among
subjects who received regadenoson were headache (97
subjects, 27.2%), dizziness (69, 19.4%), chest discom-
fort (44, 12.4%), nausea (43, 12.1%), and dyspnea (38,
10.7%) in the asthma stratum (N = 356), and headache
(62, 19.6%), dyspnea (57, 18.0%), dizziness (45,
14.2%), flushing (37, 11.7%), and chest discomfort
(35, 11.1%) in the COPD stratum (N = 316); all these
events were statistically significantly more frequent in
subjects who received regadenoson than placebo. One
serious adverse event was reported during the study in
an asthmatic subject who received regadenoson
(complete atrioventricular block; subject recovered).
This event was considered by the investigator as
probably related to regadenoson. Three serious adverse
events were reported during the study in COPD subjects
who received regadenoson; bradycardia was deemed
probably related, ECG change (T wave abnormality with
possible anterior ischemia) was deemed possibly related,
and nephrolithiasis was not considered to be related to
regadenoson by the investigators. Two further serious
adverse events (rectal hemorrhage and amyotrophic
lateral sclerosis) were experienced by subjects who
received regadenoson after the follow-up visit, neither of
which was considered to be related to regadenoson.
Two regadenoson subjects in the COPD stratum
received aminophylline for treatment of adverse events;
one subject experienced bradycardia, which was treated
with aminophylline 75 mg (intravenous), and one sub-
ject experienced dyspnea, which was treated with
aminophylline 50 mg (intravenous).
The percentage of subjects with a heart rate
[100 bpm at any assessment up to 1 hour post-study
drug administration was greater in the regadenoson
group than in the placebo group in both the asthma


















Placebo 15.2% 98.7% 83.5% Minute 5
Regadenoson 12.4% 97.9% 85.5% Minute 30
COPD stratum
Placebo 14.4% 95.2% 80.8% Hours 3–7
Regadenoson 12.7% 98.2% 85.5% Minute 30
FEV1, greatest %
decrease Asthma stratum
Placebo 0.74 L (32.9%) 2.25 L 1.51 L Hour 2
Regadenoson 0.64 L (34.4%) 1.86 L 1.22 L Minute 15
COPD stratum
Placebo 0.50 L (29.9%) 1.67 L 1.17 L Hour 2





Placebo 1.06 L (32.3%) 3.28 L 2.22 L Minute 15
Regadenoson 1.11 L (33.1%) 3.35 L 2.24 L Minute 15
COPD stratum
Placebo 0.55 L (28.8%) 1.91 L 1.36 L Minute 5
Regadenoson 0.79 L (30.7%) 2.57 L 1.78 L Minute 15
COPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second.
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stratum (16.4% [58/354] vs 0.6% [1/173], respectively)
and the COPD stratum (11.1% [35/315] vs 0.7% [1/149],
respectively). Furthermore, from examination of ECGs,
mean increases in heart rate from baseline to 5 minutes
post-dose were greater in subjects who received regad-
enoson than placebo in the asthma stratum (17.2 vs
0.3 bpm, respectively) and the COPD stratum (14.5 vs
-0.3 bpm, respectively). The differences between the
regadenoson and the placebo groups are consistent with
the cardiovascular effects expected for regadenoson,11
and lessened at each post-baseline assessment in both
disease strata. At any of the intervals assessed, the
percentage of subjects with an ECG abnormality was
similar in the regadenoson and the placebo groups for
both disease strata.
Systolic blood pressure of C180 mm Hg with at
least a 20 mm Hg increase from baseline at any assess-
ment up to 1 hour post-study drug administration was
also observed more frequently in subjects in the COPD
stratum who received regadenoson than those who
received placebo (2.8% [9/316] vs 0.7% [1/151],
respectively). No other significant differences were
observed between the regadenoson and the placebo
groups with regard to heart rate or blood pressure.
DISCUSSION
Regadenoson was not statistically significantly dif-
ferent from placebo with respect to the percentage of
subjects experiencing a [15% decrease in FEV1 from
baseline to 2 hours post-baseline, or at any assessment
up to the follow-up visit (24 hours post-baseline) in
either the asthma or the COPD stratum. The number of
subjects with a concurrent [15% decrease in FEV1 and
drop in oxygen saturation to\92% of the baseline value
was the same in the regadenoson and placebo groups
(two subjects in each). The change in FEV1 was not
affected by baseline disease severity in either the asthma
or the COPD stratum.
The asthma and the COPD severity classification
criteria used in this study are clinical practice guidelines
intended to guide patient management.9,10 Neither are
validated for categorization of disease severity. The
GOLD COPD guidelines include categorization of
severity based on post-bronchodilator FEV1 and the
NHLBI asthma criteria are based on the type and dose of
asthma medication. Asthma is a dynamic disease, with
patients experiencing fluctuations in symptom frequency
and severity, such that the treatment that a patient is
Table 6. Respiratory parameters at baseline and change at 2 hours post-baseline
Placebo Regadenoson
P valuean Mean ± SD n Mean ± SD
Asthma stratum
FEV1 (L)
Baseline 176 2.41 ± 0.689 356 2.35 ± 0.623
Change at Hour 2 174 -0.05 ± 0.160 351 -0.01 ± 0.129 .0029**
FVC (L)
Baseline 176 3.22 ± 0.883 356 3.16 ± 0.829
Change at Hour 2 174 -0.06 ± 0.208 351 -0.03 ± 0.168 .0789
FEV1/FVC ratio
Baseline 176 74.88 ± 7.510 356 74.59 ± 7.084
Change at Hour 2 174 0.16 ± 3.329 351 0.52 ± 2.562 .2087
COPD stratum
FEV1 (L)
Baseline 151 1.70 ± 0.630 316 1.70 ± 0.655
Change at Hour 2 147 -0.01 ± 0.152 313 -0.00 ± 0.159 .6189
FVC (L)
Baseline 151 2.75 ± 0.833 316 2.83 ± 0.899
Change at Hour 2 147 -0.04 ± 0.230 313 0.00 ± 0.239 .0258*
FEV1/FVC ratio
Baseline 151 61.95 ± 12.684 316 60.00 ± 13.191
Change at Hour 2 147 0.31 ± 3.177 313 -0.30 ± 3.571 .0289*
COPD, Chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; SD,
standard deviation.
*,**Statistical significance at level of P = .05 and P = .01, respectively.
aF test from ANCOVA with treatment and investigator site as main effects and baseline value as a covariate in the model.
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receiving (on which the NHLBI asthma criteria are
based) may, and will, vary over time. In order to
optimally assess asthma severity, interpretation of the
patient’s treatment history in the period preceding the
study is needed. In this study, that history involved the
30 days preceding administration of study drug. Fur-
thermore, in accordance with the inclusion/exclusion
criteria of the study, subjects were not randomized if
they changed their asthma treatment regimen or expe-
rienced an exacerbation due to their asthma. It is,
therefore, thought that the asthma and the COPD criteria
employed in this study are a realistic proxy of disease
severity.
Although the subjects in this study had a wide range
of asthma and COPD severity, their underlying disease
was required by the inclusion/exclusion criteria of the
study to be stable. Thus, the results of this study cannot
be extrapolated for subjects who have acute exacerba-
tion of their underlying illness necessitating a change in
their treatment regimen. Nonetheless, we believe that
this study achieved the aim of evaluating the safety of
regadenoson in subjects with a wide range of severity of
asthma or COPD. Furthermore, consistent with accepted
guidelines, the respiratory condition of patients with
asthma or COPD should be as stable as possible prior to
MPI with any pharmacologic stress agent.3
The overall incidence of selected respiratory
adverse events was statistically significantly higher in
the regadenoson group compared with placebo in both
the asthma and the COPD strata, but this did not result in
a greater use of short-acting b2 agonists at the time of
these selected respiratory adverse events. The types of
adverse events reported in this study were similar to
those observed in other studies of regadenoson.12-14
Severe bronchoconstrictive reactions have been
reported following adenosine and dipyridamole, and
although rare, are of serious concern to clinicians.15,16 In
this study, 672 subjects received regadenoson. A sample
size of 300 receiving regadenoson in each disease
stratum would be able to detect an adverse event as rare
as 54 per 10,000 with approximately 80% probability,
and 76 per 10,000 with approximately 90% probability.
Although no such severe reactions occurred during this
study, this does not exclude the possibility of these
occurring when adenosine receptor agonists are used in
the clinical setting. Consistent with the caution advised
in the regadenoson prescribing information, physicians
should have the appropriate medications and resuscita-
tion equipment available during regadenoson stress in
patients with asthma or COPD in the event of
bronchoconstriction.11
The number of subjects in this study with known
coronary artery disease was 15.3% (N = 153) compared
with 77.0% (N = 1,441) in the pivotal ADVANCE MPI
(ADenosine Versus regAdeNoson Comparative Evalua-
tion for Myocardial Perfusion Imaging) trials.12,14 In
Table 7. Short-acting bronchodilator use at the time of selected symptomatic respiratory adverse
events
Parameter n (%)









Within 2 hours of study drug administration
Subjects who experienced a respiratory
symptomatic adverse event of interesta
3 (1.7) 42 (11.8) 5 (3.3) 58 (18.4)
Subjects who used a short-acting bronchodilatorb 3 (1.7) 3 (0.8) 5 (3.3) 12 (3.8)
Subjects using a short-acting bronchodilator at time
of selected adverse eventc
1 (0.6) 1 (0.3) 2 (1.3) 2 (0.6)
Within 24 hours of study drug administration
Subjects who experienced a respiratory
symptomatic adverse event of interesta
4 (2.3) 46 (12.9) 6 (4.0) 60 (19.0)
Subjects who used a short-acting bronchodilatorb 94 (53.4) 168 (47.2) 65 (43.0) 141 (44.6)
Subjects using a short-acting bronchodilator at time
of selected adverse eventc
2 (1.1) 5 (1.4) 2 (1.3) 5 (1.6)
COPD, chronic obstructive pulmonary disease.
aDyspnea, wheezing, obstructive airways disorder, exertional dyspnea, and tachypnea (MedDRA version 11.1 preferred terms).
bShort-acting bronchodilators defined as medications coded to drugs for obstructive airway diseases.
cUse of a short-acting bronchodilator between the start and stop time of the specified respiratory adverse event of interest for
each subject.
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order to represent patients who would be likely to be
referred for MPI, the inclusion criteria of this study were
based on risk factors for coronary artery disease, as well
as the presence of known coronary artery disease,
whereas the ADVANCE trials recruited patients who
were referred for clinically indicated MPI.
The findings of this study are consistent with the
conclusions of previous pilot studies in subjects with
asthma or COPD5,6 and indicate that the effect of
regadenoson on the pulmonary function of these high-
risk subjects is not clinically meaningfully different
from placebo with respect to the percentage of subjects
experiencing a[15% decrease in FEV1 from baseline to
any assessment up to the 24-hour post-baseline follow-
up visit. Although no subjects experienced severe
bronchoconstriction in this study, the occurrence of
these reactions cannot be ruled out with adenosine
receptor agonists, such that the drug should be used with
caution in patients with asthma and COPD, consistent
with the prescribing information.11 This information
should be useful when considering selection of regad-
enoson as a pharmacologic stress agent for MPI in these
patient populations.
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